Medtronic to acquire Contego Medical, expanding access to next-generation carotid therapies
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Medtronic (MDT) plans to acquire privately held Contego Medical in a transaction valued at $380 million, with potential payments after acquisition. Medtronic expects completion in its fiscal third quarter, subject to customary closing conditions.
The acquisition would add the recently FDA-approved Neuroguard IEP Direct System for carotid artery treatment and Excipio devices for removing blood clots from peripheral vessels. In the prospective, multicenter PERFORMANCE III study, Neuroguard IEP Direct recorded zero strokes, neurological deaths, cranial nerve injuries or myocardial infarctions at 30 days.
Medtronic expects the acquisition to be minimally dilutive to adjusted earnings per share in FY27 and FY28, meaning a small reduction, and neutral to accretive thereafter. The planned deal builds on an exclusive U.S. distribution agreement with Contego first announced in January 2025.
Positive
- Minor point. Forward-looking: it has not happened yet and may not happen.Planned $380 million Contego acquisition would expand Medtronic's carotid and peripheral vascular treatment portfolio.
- Minor point. Forward-looking: it has not happened yet and may not happen.Recently FDA-approved Neuroguard IEP Direct System is included in the planned acquisition.
- Minor pointPERFORMANCE III recorded zero strokes, neurological deaths, cranial nerve injuries and myocardial infarctions at 30 days.
- Minor point. Forward-looking: it has not happened yet and may not happen.Excipio thrombectomy devices would complement Medtronic's Liberant system for peripheral vascular disease.
Negative
- Minor point. Forward-looking: it has not happened yet and may not happen.Potential post-acquisition payments accompany the transaction's $380 million valuation.
- Minor point. Forward-looking: it has not happened yet and may not happen.Adjusted EPS is expected to be minimally diluted in FY27 and FY28, then neutral to accretive.
AI-generated analysis. How Rhea-AI works. Not financial advice.
The acquisition will build on the company's successful, exclusive
"With this acquisition, Medtronic is taking another important step to strengthen our leadership in the treatment of carotid artery disease," said David Moeller, senior vice president and president of Medtronic Peripheral Vascular Health, which is part of the company's Cardiovascular portfolio. "By pairing Medtronic's deep clinical expertise in peripheral and neurovascular technologies with Contego's next-generation treatments backed by strong and consistent clinical data,† we intend to become an undisputed leader in carotid revascularization."
Carotid artery disease occurs when the carotid arteries, the major blood vessels supplying the brain, become narrowed or blocked. Plaque can then rupture or embolize and lead to a stroke, accounting for about
"Contego was founded to address unmet needs in clinical practice by developing technologies designed to improve outcomes while simultaneously simplifying procedures. Deepening our partnership with Medtronic is an exciting next chapter," said Ravish Sachar, MD, Founder and Chief Executive Officer of Contego Medical. "We're proud of our team and grateful to the physicians, study sites, employees, and investors who helped bring these technologies to patients."
The planned acquisition includes Contego's recently FDA-approved Neuroguard IEP*™ Direct System, the first and only transcarotid artery revascularization system with integrated embolic protection (TCAR-IEP) in addition to flow reversal. In the prospective, multicenter PERFORMANCE III study,6 the Neuroguard IEP Direct System demonstrated exceptional outcomes at 30 days:
- Zero strokes6
- Zero neurological deaths6
- Zero cranial nerve injuries6
- Zero myocardial infarctions6
"Stroke-related disability underscores the need for more innovative treatment options — and the opportunity to make a meaningful difference for patients," said Linnea Burman, senior vice president and president of Medtronic Neurovascular. "We are committed to delivering technologies designed to reduce stroke risk and advance patient care. Our planned acquisition of Contego builds on that commitment, helping physicians bring meaningful innovation to more patients with carotid artery disease."
Beyond carotid revascularization, the acquisition includes Contego's Excipio*™ thrombectomy devices, which complement Medtronic's Liberant™ thrombectomy system in the treatment of peripheral vascular disease.
Medtronic expects to complete the transaction in the third quarter of its fiscal year, subject to customary closing conditions. Valued at
About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in
About Contego Medical, Inc.
Contego Medical, Inc. is the leader in developing state-of-the-art solutions that transform complex cases into simplified procedures. The company's portfolio of integrated, multi-functional products is designed to improve patient outcomes and procedural efficiency in the treatment of carotid and peripheral vascular disease. Contego's portfolio includes the Neuroguard IEP*™ System, the Neuroguard IEP*™ Direct System, and Excipio*™ Thrombectomy Device. Contego's growth and innovation have been supported by leading healthcare investors, including Hatteras Venture Partners, U.S. Venture Partners, Lightstone Ventures, and Amzak Health.
Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the U.S. Securities and Exchange Commission. Actual results may differ materially from anticipated results.
Contacts:
Justin Paquette
Public Relations
+1-612-271-7935
Ingrid Goldberg
Investor Relations
+1-763-505-2696
Footnotes
™*Third-party brands are trademarks of their respective owners. All other brands are trademarks of a Medtronic company.
† First 3-in-1 carotid artery stenting system compared to standalone stents, balloons, and filters. Clinical outcomes claims are based on prospective, multicenter studies and registries evaluating Contego Medical technologies, including the PERFORMANCE I, PERFORMANCE II, PERFORMANCE III, and Paladin studies. Individual study results may vary, and outcomes should not be directly compared across studies.
References
- Musialek P et al. Cardiovasc Res. 2023;121(1):13-43. doi:10.1093/cvr/cvad135
- Antonius Carotid Endarterectomy, Angioplasty, and Stenting Study Group. Transcranial Doppler monitoring in angioplasty and stenting of the carotid bifurcation. J Endovasc Ther. 2003 Aug;10(4):702-710.
- Martin JB, Pache JC, Treggiari-Venzi M, et al. Role of the distal balloon protection technique in the prevention of cerebral embolic events during carotid stent placement. Stroke. 2001 Feb;32(2):479-484.
- Ackerstaff RG, Suttorp MJ, van den Berg JC, et al. Prediction of early cerebral outcome by transcranial Doppler monitoring in carotid bifurcation angioplasty and stenting. J Vasc Surg. 2005;41(4):618-624.
- Hellings WE, Ackerstaff RG, Pasterkamp G, De Vries JP, Moll FL. The carotid atherosclerotic plaque and microembolisation during carotid stenting. J Cardiovasc Surg (Torino). 2006 Apr;47(2):115-126.
- Lyden SP, Mendes RR, Mouawad NJ, Mallios A, Mathews SJ, Pugar CE, et al; PERFORMANCE III Investigators. Thirty-day outcomes following transcarotid artery revascularization with integrated embolic protection: The PERFORMANCE III study. J Vasc Surg. 2026;84(4):951-960.e3. doi:10.1016/j.jvs.2026.05.027.

View original content to download multimedia:https://www.prnewswire.com/news-releases/medtronic-to-acquire-contego-medical-expanding-access-to-next-generation-carotid-therapies-302939849.html
SOURCE Medtronic plc
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How much is Medtronic's planned Contego Medical acquisition worth, and when will it close?
The planned acquisition is valued at $380 million, with potential payments after acquisition. Medtronic expects to complete the transaction in its fiscal third quarter, subject to customary closing conditions.
How will the Contego acquisition affect Medtronic's earnings?
Medtronic expects the acquisition to be minimally dilutive to adjusted earnings per share in FY27 and FY28 and neutral to accretive thereafter. This means a small reduction in adjusted earnings per share initially, followed by no effect or an increase.